![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ASB9 |
Gene summary for ASB9 |
![]() |
Gene information | Species | Human | Gene symbol | ASB9 | Gene ID | 140462 |
Gene name | ankyrin repeat and SOCS box containing 9 | |
Gene Alias | ASB9 | |
Cytomap | Xp22.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RBW7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140462 | ASB9 | HCC1_Meng | Human | Liver | HCC | 2.52e-31 | 4.79e-02 | 0.0246 |
140462 | ASB9 | S016 | Human | Liver | HCC | 1.65e-03 | 1.66e-01 | 0.2243 |
140462 | ASB9 | S027 | Human | Liver | HCC | 5.30e-05 | 4.76e-01 | 0.2446 |
140462 | ASB9 | S028 | Human | Liver | HCC | 1.44e-12 | 5.37e-01 | 0.2503 |
140462 | ASB9 | S029 | Human | Liver | HCC | 2.89e-15 | 6.56e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
GO:004573222 | Liver | HCC | positive regulation of protein catabolic process | 163/7958 | 231/18723 | 4.00e-18 | 4.69e-16 | 163 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASB9 | SNV | Missense_Mutation | rs780881880 | c.593N>A | p.Gly198Asp | p.G198D | Q96DX5 | protein_coding | tolerated(0.28) | benign(0.029) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
ASB9 | SNV | Missense_Mutation | rs779187083 | c.347A>G | p.Asp116Gly | p.D116G | Q96DX5 | protein_coding | tolerated(0.33) | benign(0.411) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
ASB9 | SNV | Missense_Mutation | c.221N>G | p.His74Arg | p.H74R | Q96DX5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ASB9 | SNV | Missense_Mutation | novel | c.364C>A | p.Leu122Met | p.L122M | Q96DX5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ASB9 | SNV | Missense_Mutation | c.769T>C | p.Ser257Pro | p.S257P | Q96DX5 | protein_coding | tolerated(0.15) | benign(0.114) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
ASB9 | insertion | Nonsense_Mutation | novel | c.745_746insAGGGCATACGTTAATGTAGGATGTATATGTCCCCTCCTCCATC | p.Phe249Ter | p.F249* | Q96DX5 | protein_coding | TCGA-A2-A0D4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
ASB9 | insertion | Nonsense_Mutation | novel | c.530_531insGATCATTCTCTGACATCA | p.Asn177delinsLysIleIleLeuTerHisHis | p.N177delinsKIIL*HH | Q96DX5 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ASB9 | deletion | Frame_Shift_Del | novel | c.45delG | p.Pro16GlnfsTer14 | p.P16Qfs*14 | Q96DX5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
ASB9 | SNV | Missense_Mutation | novel | c.601N>C | p.Ser201Pro | p.S201P | Q96DX5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ASB9 | SNV | Missense_Mutation | novel | c.694N>T | p.Gly232Cys | p.G232C | Q96DX5 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-ZJ-A8QO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |